Villarrubia, JE, Gordoa, TA, Mellado-González, B, Duran, I, Pinto, A, Sanchez, A, Pous, AF, Vazquez-Estevez, S, Puente, J, Grande, E, Climent, MA, Maroto-Rey, P, Perez-Gracia, JL, Aix, SP, Castellano, D, Gonzalez-Billalabeitia, E. Peapod FOS trial: A phase 2 clinical trial of pembrolizumab in combination with carboplatin and cabazitaxel in aggressive variant metastatic castration-resistant prostate cancer.. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(4_SUPPL)DOI:10.1200/JCO.2024.42.4_suppl.TPS238. PMID:. IF:41.900(Q1/1D).

Pacheco-Barcia, V, Méndez, AM, Carmona-Bayonas, A, Gallego, J, Franco, CF, Adeva, J, Cerdà, P, Cabezon-Gutierrez, L, Custodio-Cabello, S, Ghanem, I, Hernandez, I, Lamarca, A, Laquente, B, López-Alfonso, A, Lago, NM, Macarulla, T, Peiro, I, Visa, L, Jimenez-Fonseca, P, Muñoz, A. Nutritional impact and prognostic role of systemic inflammatory response index (SIRI) in advanced pancreatic cancer: PANTHEIA-Spanish Society of Medical Oncology (SEOM) study results.. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(3_SUPPL)DOI:10.1200/JCO.2024.42.3_suppl.623. PMID:. IF:41.900(Q1/1D).

Modest, DP, Fakih, M, Salvatore, L, Esaki, T, Lopez-Bravo, DP, Taieb, J, Karamouzis, M, Ruiz-Garcia, E, Kim, TW, Kuboki, Y, Meriggi, F, Cunningham, D, Yeh, KH, Cremolini, C, Tran, Q, Chan, E, Chao, J, Majer, IM, Pietrantonio, F. Health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) treated with sotorasib and panitumumab (pmab) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in CodeBreaK 300.. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(3_SUPPL)DOI:10.1200/JCO.2024.42.3_suppl.10. PMID:. IF:41.900(Q1/1D).

Contreras-Toledo, D, Jiménez-Fonseca, P, López, CL, Montes, AF, Muñoz, AML, Rivera, FV, Alonso, V, Alcaide, J, Salvà, F, Rúa, MC, Guillot, M, Carnicero, AM, Mate, RJ, García, SC, Martínez, EA, Astorga, BG, Fernandez-Diaz, AB, Villaroel, PG, Manrique, ACV, Sosa, MM, Alonso, B, Castiñeiras, AC, López, CC, Aparicio, J, Carmona-Bayonas, A. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?. BRITISH JOURNAL OF CANCER. 2024; 130(5)DOI:10.1038/s41416-023-02563-w. PMID:38191609. IF:6.800(Q1/2D).

Mateo, FJP, Guasch, AD, Pineda, JAG, Manrique, ACV, Cullell, BM, López-Bravo, DP, Díaz, JG, Cascón, AP, Freiria, XB. Capecitabine-Related Thrombotic Microangiopathy. Journal Of Gastrointestinal Cancer. 2024; 55(2)DOI:10.1007/s12029-023-00993-6. PMID:38175385. IF:(Q/D).

Shachar, SS, Korzets, Y, Shepshelovich, D, Zlothover, N, Amir, E, Tibau, A, Goldvaser, H. Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review. CANCER TREATMENT REVIEWS. 2024; 122DOI:10.1016/j.ctrv.2023.102666. PMID:38064877. IF:10.500(Q1/1D).

Grünwald, V, Powles, T, Eto, M, Kopyltsov, E, Rha, SY, Porta, C, Motzer, R, Hutson, TE, Méndez-Vidal, MJ, Hong, SH, Winquist, E, Goh, JC, Maroto, P, Buchler, T, Takagi, T, Burgents, JE, Perini, R, He, C, Okpara, CE, McKenzie, J, Choueiri, TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Onkourologiya. 2024; 20(1)DOI:10.17650/1726-9776-2024-20-1-24-35. PMID:. IF:(Q/D).

Ahn, MJ, Cho, BC, Felip, E, Korantzis, I, Ohashi, K, Majem, M, Juan-Vidal, O, Handzhiev, S, Izumi, H, Lee, JS, Dziadziuszko, R, Wolf, J, Blackhall, F, Reck, M, Alvarez, JB, Hummel, HD, Dingemans, AMC, Sands, J, Akamatsu, H, Owonikoko, TK, Ramalingam, SS, Borghaei, H, Johnson, ML, Huang, S, Mukherjee, S, Minocha, M, Jiang, TY, Martinez, P, Anderson, ES, Paz-Ares, L. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(22)DOI:10.1056/NEJMoa2307980. PMID:37861218. IF:96.300(Q1/1D).

Rodero, BS, Martínez-Toledo, C, Nadal, E, Molina-Alejandre, M, Campelo, RG, Gil-González, A, Massuti, B, García-Grande, A, Dómine, M, Insa, A, Carpeño, JD, Vence, GH, Majem, M, Martinez-Marti, A, Megias, D, Lobato, D, Collazo-Lorduy, A, Calvo, V, Provencio, M, Cruz-Bermúdez, A. Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial). OncoImmunology. 2025; 14(1)DOI:10.1080/2162402X.2025.2513109. PMID:40468805. IF:6.300(Q1/2D).

Cerezuela-Fuentes, P, de la Rosa, CA, Crespo, G, Berciano-Guerrero, MA, Soria, A, Muñoz-Couselo, E, Castro, RL, Majem, M, de Miguel, PA, Manzano, JL, Bellido, L, Lecumberri, MJ, Subias, MC, Guzmán, JCV, Hernández, B, Espinosa, E, Puértolas, T, Sanz, LG, Martínez, JM, Abril, VP, Algarra, SM, Márquez-Rodas, I. Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study. MELANOMA RESEARCH. 2025; 35(6)DOI:10.1097/CMR.0000000000001062. PMID:40901826. IF:1.900(Q3/6D).

Hecht, JR, Park, YS, Tabernero, J, Lee, MA, Lee, SHY, Virgili, AC, van den Eynde, M, Fontana, E, Fakih, M, Asghari, G, So, JE, Stein, A, Dubreuil, O, Bodnar, L, He, CS, Wang, G, Smith, R, Eng, C, Saeed, A. Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. LANCET. 2025; 406(10517)DOI:10.1016/S0140-6736(25)02025-2. PMID:41130252. IF:88.500(Q1/1D).

Fernández-Morata, J, Pollán, M, de Larrea-Baz, NF, Pachon-Olmos, V, García-Pérez, J, Castello, A, Sierra, MA, Lucas, P, Llobet, R, Stradella, A, Cantos, B, Cajal, TRY, Santisteban, M, Seguí, MA, Bertrán, AS, Granja, M, Camps-Herrero, J, Recalde, S, Nuñez-García, B, Verges, NC, Pérez-Gomez, B, Pastor-Barriuso, R, Lope, V. Mammographic density and breast cancer pathological subtypes by menopausal status and body mass index (vol 27, 187, 2025). BREAST CANCER RESEARCH. 2025; 27(1)DOI:10.1186/s13058-025-02169-5. PMID:41225573. IF:5.600(Q1/2D).

Simoes, AR, González, SC, Lopez-Doldan, MD, Duran, G, Fernández-Montes, A, Fernandez, MP, Fernandez, MS, Mata, JG, Paez, D, Riera, P, Guino, E, Lopez-Fernandez, L, de Santiago, BG, Aspiroz, EL, Rojas, A, Castells, A, Castellvi-Bel, S, Ponte, CR, Vymetalkova, V, Carracedo, A, Fernandez-Rozadilla, C. Novel approaches for the discovery of pharmacogenetic biomarkers of chemotoxicity in patients with colorectal cancer. BRITISH JOURNAL OF PHARMACOLOGY. 2025; 182(21)DOI:10.1111/bph.70051. PMID:40624839. IF:7.700(Q1/1D).

Isla, D, Zugazagoitia, J, Arriola, E, García-Campelo, R, Blanco, CM, Diz-Taín, MP, Lopez-Brea, M, Moreno-Vega, AL, León-Mateos, L, Oramás, J, Gutiérrez-Calderón, V, Majem, M, Sánchez-Hernández, A, Aguado, C, Alvarez-Cabellos, R, Massutí, B, Moreno, A, Fírvida-Pérez, JL, Valdivia, J, González-Cordero, M, Zafra-Poves, M, Dómine, M, Garcia-Navalon, FJ, Villanueva, N, Provencio, M, Juan-Vidal, O, Rivas-Corredor, C, García, MEO, Palmero, R, López-Castro, R, Carcereny, E, Lechuga, JL, Domínguez, M, Callejo, A, Paz-Ares, L. Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial. LUNG CANCER. 2025; 209DOI:10.1016/j.lungcan.2025.108763. PMID:41033130. IF:4.400(Q1/2D).

Soler, G, Grávalos, C, Rivera, F, Safont, MJ, Virgili, AC, Valladares-Ayerbes, M, Ferreiro-Monteagudo, R, Ortiz-Morales, MJ, Polo-Marques, E, Kornusova-Bersheva, I, Soustre, E, Yao, WY, Élez, E. Predictive factors of efficacy for FTD/TPI plus bevacizumab in refractory metastatic colorectal cancer patients: a subanalysis of the Spanish cohort from the SUNLIGHT phase III trial. Clinical & Translational Oncology. 2025; 27(11)DOI:10.1007/s12094-025-03907-z. PMID:40338282. IF:2.500(Q3/6D).

Cortellini, A, Garbo, E, La Cava, G, Citarella, F, Santo, V, Brunetti, L, Pinato, DJ, Naidoo, J, Loza, M, Genova, C, Gettinger, S, Kim, SY, Jayakrishnan, R, El Zarif, T, Russano, M, Pecci, F, Di Federico, A, Montrone, M, Owen, DH, Signorelli, D, Li, MJ, Camerini, A, Halmos, B, Vincenzi, B, Metro, G, Yendamuri, S, Grossi, F, Josephides, E, Tomasik, B, Giusti, R, Bria, E, Sebastian, M, Rost, M, Acker, F, Landi, L, Mazzoni, F, Morabito, A, Leonetti, A, Cantini, L, Mountzios, G, Kalvapudi, S, O'Reilly, D, Karapanagiotou, E, Monnet, I, Baena, J, Macerelli, M, Majem, M, Piedra, A, Cortinovis, DL, Tonini, G, Minuti, G, Mezquita, L, Gorria, T, Beninato, T, Lo Russo, G, Prelaj, A, De Giglio, A, Biello, F, Nana, FA, Dingemans, AMC, Aerts, JG, Ferrara, R, Abu Hejleh, T, Takada, K, Naqash, AR, Garassino, MC, Wakelee, HA, Nassar, A, Ricciuti, B, Soda, P, Caruso, CM, Guarrasi, V. Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression = 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity. LUNG CANCER. 2025; 209DOI:10.1016/j.lungcan.2025.108799. PMID:41108882. IF:4.400(Q1/2D).

Yang, JCH, Wang, MZ, Doucet, L, Fan, Y, Lv, DQ, Sun, ML, Huang, DZ, Greillier, L, Planchard, D, Hong, QY, Mazieres, J, Felip, E, Li, XY, Hu, Y, Fang, J, Bazhenova, L, Ghiringhelli, F, Dols, MAC, Rodriguez, LPA, Bearz, A, Pellini, B, Kim, YJ, Bosch-Barrera, J, Shim, BY, Luo, YH, Tiseo, M, Yang, TY, Carcereny, E, Memmott, RM, Zalcman, G, Carpeno, JD, Di Noia, V, Parra, HS, Streich, G, Lee, DH, Shum, E, Han, JY, Jaime, JC, Brungs, D, John, T, D'Arcangelo, M, Joaquin, AB, Liu, GF, Antonuzzo, L, Hinojal, GF, Le, XN, Zheng, L, Jänne, PA. Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(29)DOI:10.1200/JCO-25-00788. PMID:40923280. IF:41.900(Q1/1D).

de la Peña, FA, Martínez-Ramos, D, Juan-Vidal, O, Gómez-Balaguer, M, Miguélez, M, Páez, D, Arrazubi, V, González, CH. Oncological needs in transgender patients. Clinical & Translational Oncology. 2025; 27(10)DOI:10.1007/s12094-025-03917-x. PMID:40251439. IF:2.500(Q3/6D).

Suárez, C, Torras, OR, Barrera, RM, Sánchez, AR, Palacios, GA, Manshino, AMB, Núñez, NF, Vidal, MJM, Carbonero, IG, Calvo, OF, Sarrió, RG, Herrero, GC, Afonso, JA, Fita, MJJ, Padró, JG, Quintela, ML, Rodriguez-Vida, A, Perez, CH, Colmenero, AM, Martin, RC, de España, CG, Palau, CM, Ortega, EM, Gallardo, E. Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study. Clinical Genitourinary Cancer. 2025; 23(5)DOI:10.1016/j.clgc.2025.102402. PMID:40830022. IF:2.700(Q2/3D).

Palmerini, E, Meazza, C, Tamburini, A, Márquez-Vega, C, Bisogno, G, Fagioli, F, Ferraresi, V, Milano, GM, Coccoli, L, Rubio-San-Simón, A, Gallego, O, Riestra, MEL, Manzitti, C, Mora, J, Vaz-Salgado, MA, Luksch, R, Mata, C, Pierini, M, Carretta, E, Cesari, M, Paioli, A, Marrari, A, Scotlandi, K, Serra, M, Asaftei, SD, Gambarotti, M, Picci, P, Ferrari, S, Valverde, C, Ibrahim, T, Broto, JM. Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(28)DOI:10.1200/JCO-25-00210. PMID:40825172. IF:41.900(Q1/1D).

Tibau, A, Romano, A, Liu, ITT, Han, J, Cliff, ERS, Kesselheim, AS. Assessing outcomes emerging after conversion to regular approval for cancer drug indications granted accelerated approval, 1992-2021. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2025; 117(10)DOI:10.1093/jnci/djaf195. PMID:40690366. IF:7.200(Q1/2D).

López-Fernández, A, Pardo, M, Pérez-Ballestero, E, Darder, E, Alfonso, R, Torres-Esquius, S, Garcés, VN, Cajal, TRY, Brunet, J, Balmaña, J. Exploring communication preferences for disclosing breast cancer risk in women with a family history. Journal of Genetic Counseling. 2025; 34(5)DOI:10.1002/jgc4.70114. PMID:40965181. IF:1.900(Q2/5D).

Ospina-Serrano, AV, González-Larriba, JL, Nadal, E, Trancho, FH, Bosch-Barrera, J, Calvo, V, Bolufer-Nadal, S, de la Cruz, JLCC, Macía-Vidueira, I, Alvarez-Kindelán, A, Del Barco-Morillo, E, Bernabé-Caro, R, Casal-Rubio, J, Cilleruelo-Ramos, A, Cobo-Dols, M, Dómine-Gómez, M, Figueroa-Almánzar, S, Insa-Mollá, A, Jarabo-Sarceda, JR, Jiménez-Maestre, U, López-Castro, R, Majem, M, Martinez-Marti, A, Téllez, EM, Sánchez-Lorente, D, López-Valcárcel, M, Couñago, F, Garcia-Campelo, R, de Castro, J, Massuti-Sureda, B, Provencio, M. Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement. Translational Lung Cancer Research. 2025; 14(9)DOI:10.21037/tlcr-2025-619. PMID:41132973. IF:3.500(Q1/3D).

Di Maio, M, Gonzalez-Billalabeitia, E, Marandino, L, Maroto, P, Timsit, MO, Luccarini, I, Robinson, P, Van Sanden, S, Hadaschik, BA. A network meta-analysis of the safety of systemic treatments in patients with metastatic hormone-sensitive prostate cancer. Frontiers in Oncology. 2025; 15DOI:10.3389/fonc.2025.1468928. PMID:41059299. IF:3.300(Q2/4D).

Jenei, K, Hahn, G, Kesselheim, AS, Tibau, A. Trends in time to withdrawal and full approval of accelerated approval cancer drug indications (1992-2024). Journal Of Cancer Policy. 2025; 45DOI:10.1016/j.jcpo.2025.100597. PMID:40472969. IF:(Q/D).

Remon, J, Bironzo, P, Girard, N, Bigay-Game, L, Juan-Vidal, O, de Castro, J, Reguart, N, Greillier, L, Cousin, S, Dansin, E, Majem, M, Bernabe, R, Martinez, JM, Diaz, M, Meya, A, Alcalá-López, D, Garcia-Sanz, A, Righi, L, Novello, S, Besse, B. Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. LANCET ONCOLOGY. 2025; 26(9)DOI:10.1016/S1470-2045(25)00300-6. PMID:40907517. IF:35.900(Q1/1D).

Tombal, B, Choudhury, A, Saad, F, Gallardo, E, Soares, A, Loriot, Y, Mcdermott, R, Rodriguez-Vida, A, Velho, PI, Nolè, F, Cruz, F, Roumeguere, T, Daugaard, G, Yamamura, R, Bompas, E, Maroto, P, Veiga, FG, Skoneczna, I, Trindade, KMD, Carcano, FM, Lecouvet, F, Coens, C, Poncet, C, Fournier, B, Gillessen, S, Crua, F. Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial. ANNALS OF ONCOLOGY. 2025; 36(9)DOI:10.1016/j.annonc.2025.05.011. PMID:40450503. IF:65.400(Q1/1D).

de Bono, JS, Williams, A, Melero, I, Jayaram, A, Hawley, JE, de Speville, BD, Moreno, I, Castellano, D, Reig, O, Knapen, DG, Anguera, G, Martinez, J, Gort, E, de Jonge, M, Alonso-Romero, JL, Boni, V, Perez-Gracia, JL, Falcon, A, de Groot, DJ, Pierce, AJ, Leishman, AJ, Lloyd, P, Bartlett, PD, Bland-Ward, P, Chau, A, Song, MJ, Duffy, K, Hashimoto, K, de Vries, E. A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors. CLINICAL CANCER RESEARCH. 2025; 31(16)DOI:10.1158/1078-0432.CCR-24-3581. PMID:40094417. IF:10.200(Q1/1D).

López-Fernández, A, Duran-Lozano, L, Villacampa, G, Pardo, M, Pérez, E, Darder, E, Vallmajó, A, Alfonso, R, Cruellas, M, Roqué, A, Cartró, M, Bareas, A, Carrasco, E, Rezqallah, A, Jimenez-Macedo, AR, Torres-Esquius, S, Torres, M, Lopez, C, Espinosa, M, Teulé, A, Munté, E, Tuset, N, Diez, O, Feliubadaló, L, Lázaro, C, Llort, G, Carver, T, Ficorella, L, Mavaddat, N, Mercadé, A, Antoniou, AC, Brunet, J, Cajal, TRY, Balmaña, J. A randomized study of 2 risk assessment models for individualized breast cancer risk estimation. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2025; 117(8)DOI:10.1093/jnci/djaf067. PMID:40170233. IF:7.200(Q1/2D).

van der Heijden, MS, Powles, T, Gupta, S, Loriot, Y, Galsky, MD, Valderrama, BP, Sridhar, SS, Yu, EY, Iyer, G, Kikuchi, E, Castellano, D, Hoffman-Censits, J, Drakaki, A, Mar, N, Rey, JPM, Vulsteke, C, Arafat, W, Duran, I, Dawson, NA, Swami, U, Gorla, S, Moreno, BH, Yu, X, Lu, YT, Bedke, J. Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. ESMO Open. 2025; 10(8)DOI:10.1016/j.esmoop.2025.105544. PMID:40795788. IF:8.300(Q1/2D).

Zapatero, A, Alonso-Gordoa, T, Antolín, AR, Couñago, F, Sanmamed, N, Esteban, MD, Valcárcel, ML, Manneh, R, Borque-Fernando, A, González, NS, Maroto, P. Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach. Oncology Reviews. 2025; 19DOI:10.3389/or.2025.1599292. PMID:40787089. IF:(Q/D).

Aggarwal, C, Martinez-Marti, A, Majem, M, Barlesi, F, Carcereny, E, Chu, Q, Monnet, I, Sánchez-Hernández, A, Dakhil, S, Camidge, DR, Pillet, M, Brown, M, Paliompeis, C, Dowson, A, Cooper, ZA, Kumar, R, Herbst, RS. Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer Update From the COAST Randomized Clinical Trial. JAMA Network Open. 2025; 8(7)DOI:10.1001/jamanetworkopen.2025.18440. PMID:40663352. IF:9.700(Q1/1D).

Uyar, GC, Mirallas, O, Baskurt, K, Martin-Cullell, B, Yesilbas, E, Recuero-Borau, J, Kaya, S, Garcés, VN, Yücel, SE, Cano, KSV, Gómez-Puerto, D, Gómez, AP, de Torres, CS, Öksüzoglu, ÖBÇ, Serradell, S, Dienstmann, R, Sutcuoglu, O. Prediction of 90-day mortality among cancer patients with unplanned hospitalisation: a retrospective validation study of three prognostic scores. Lancet Regional Health-Europe. 2025; 54DOI:10.1016/j.lanepe.2025.101317. PMID:40672056. IF:13.000(Q1/1D).

Cappuzzo, F, Zvirbule, Z, Korbenfeld, E, Kolb-Sielecki, J, Isla, D, Szczesna, A, Sanchez, AYC, Bustillos, A, Liu, XY, Young, F, Tosti, N, Monteiro, MF, Majem, M. Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC (vol 6, 100815, 2025). Jto Clinical And Research Reports. 2025; 6(7)DOI:10.1016/j.jtocrr.2025.100842. PMID:40534993. IF:(Q/D).

Pietrantonio, F, Salvatore, L, Esaki, T, Modest, DP, Lopez-Bravo, DP, Taieb, J, Karamouzis, MV, Ruiz-Garcia, E, Kim, TW, Kuboki, Y, Meriggi, F, Cunningham, D, Yeh, KH, Chan, EMY, Chao, JS, Tran, Q, Cremolini, C, Fakih, M. Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(19)DOI:10.1200/JCO-24-02026. PMID:40215429. IF:41.900(Q1/1D).

Bergmann, L, Albiges, L, Ahrens, M, Gross-Goupil, M, Boleti, E, Gravis, G, Flechon, A, Grimm, MO, Bedke, J, Barthélémy, P, Castellano, D, Mellado, B, Ivanyi, P, Rottey, S, Flörcken, A, Suarez, C, Maroto, P, Grünwald, V, Oosting, SF, Kopecky, J, Zschäbitz, S, Boegemann, M, Buchler, T, Niegisch, G, Goebell, PJ, Waddell, T, Joly, F, Priou, F, Retz, M, Siemer, S, Zimmermann, U, Deckbar, D, Burkholder, I, Hartmann, A, Haanen, JB. Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial. ANNALS OF ONCOLOGY. 2025; 36(7)DOI:10.1016/j.annonc.2025.03.016. PMID:40180121. IF:65.400(Q1/1D).

Da Silva, IM, Riera, P, Bernal, S, Manrique, ACV, Cullell, BM, Paez, D. Relevance of ABCG2 and SRPK1 genetic variants in irinotecan-induced severe toxicity. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.05.046. PMID:. IF:65.400(Q1/1D).

Beltran, JS, Serda, PC, Cardozo, AR, Pérez, MAM, Manrique, ACV, Paez, D, Cullell, BM. A retrospective single-center analysis of treatment strategies and real-world outcomes in locally advanced pancreatic cancer. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.05.288. PMID:. IF:65.400(Q1/1D).

Ponce, CG, Méndez, AM, Plazas, JG, Benavente, MDL, Serda, PC, Vazquez, EB, Conesa, MADLAV, Gil, RHS, Gomez, VL, Alfonso, AL, Custodio-Cabello, S, Paladines, WGP, Carmena, MD, Mercade, TM, Tabares, MLS, Martínez, IP, Gutierrez, LC, Martin, AJM, Fonseca, PJ, Pacheco-Barcia, VE. Prognostic significance of the systemic inflammation response index (SIRI) and nutritional status in metastatic pancreatic cancer: Results from the PANTHEIA-SEOM study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.05.304. PMID:. IF:65.400(Q1/1D).

Pacheco-Barcia, VE, Méndez, AM, Plazas, JG, Rus, ND, Benavente, MDL, Cullell, BM, Gomez, VL, Vazquez, EB, Conesa, MADLAV, Fernandez, SP, Alfonso, AL, Castet, F, Adeva, JA, Fabregat, C, Abad, DG, Contreras, PZ, Carmona-Bayonas, A, Fonseca, PJ, Gutierrez, LC, Martin, AJM. Impact of the systemic inflammation index (SIRI) and artificial intelligence(AI)-based muscle mass (FocusedON® software) on chemotherapy toxicity and prognosis in metastatic pancreatic cancer: A proof-of-concept from the PANTHEIA-Spanish Society of Medical Oncology (SEOM) study group. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.05.305. PMID:. IF:65.400(Q1/1D).